The purpose of this study is to investigate whether the saline-coupled bipolar sealer compared to the unipolar electrocautery provides superior hemostasis in patients undergoing primary unilateral total knee arthroplasty. This will be a prospective, randomized, single-blinded, non-inferiority study in patients scheduled for a primary unilateral total knee arthroplasty (TKA) with Dr. Eugene Krauss or Dr. Ayal Segal. The restriction of this study to two surgeons will limit variations in the outcomes being measured due to differences in surgical technique.

Total joint arthroplasty can result in significant blood loss. Minimizing blood loss has led to multiple blood conservation strategies in orthopaedic procedures. The use of unipolar electrocautery or the saline-coupled bipolar sealer are methods used to reduce intraoperative bleeding. Saline-coupled bipolar sealer technology initially demonstrated promising results in the literature when it was reported that this technology had superior efficacy by reducing blood loss and transfusion requirements in orthopaedic surgery. However, the saline-coupled bipolar sealer technology comes at a significantly higher cost when compared to the unipolar electrocautery. A bipolar electrode costs an additional $450.00 per case, whereas, the unipolar electrocautery catheter is included in all the pre-packaged orthopedic surgical trays. The added cost of the saline-coupled bipolar sealer was offset by the potential savings in the reduced need for blood transfusions. A single blood transfusion is estimated to be $750-$1200. This cost includes both the direct cost of the blood and the additional nursing time needed. Recent publications have challenged the superiority of the saline-coupled bipolar sealer in hemostasis. These randomized clinical trials (RCT) have not supported superiority of this method when compared to standard unipolar electrocautery and the continued use of the saline-coupled bipolar sealer has been questioned. The purpose of this study is to investigate whether the saline-coupled bipolar sealer compared to the unipolar electrocautery provides superior hemostasis in patients undergoing primary unilateral total knee arthroplasty. This will be a prospective, randomized, single-blinded, non-inferiority study in patients scheduled for a primary unilateral TKA with Dr. Eugene Krauss or Dr. Ayal Segal. The restriction of this study to two surgeons will limit variations in the outcomes being measured due to differences in surgical technique.

Inclusion Criteria:

1. Patients scheduled for primary unilateral total knee arthroplasty with Dr. Krauss or Dr. Segal
2. Preoperative Hemoglobin >11mg/dL
3. Preoperative platelet count of >150,000
4. Age >18
5. Patient is freely able to provide consent
6. American Society of Anesthesiologists (ASA) classification I-III (Appendix J)
7. Patient willing to complete all study related procedures

Exclusion Criteria:

1. Patients allergic to aspirin
2. Patients with an intolerance to aspirin
3. Patients with a contraindication to Apixaban
4. Any patient who is not a candidate for venous thromboembolism (VTE) risk stratification according to the calculated Caprini Risk Assessment Score. This includes, but is not limited to, any patient who cannot be prescribed ASA 81 mg bid or Apixiban 2.5 mg bid for VTE prophylaxis
5. Patients who for any reason are not a candidate for the use of the monopolar electrocautery
6. History of venous thromboembolism (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)) within 12 months prior to the date of surgery
7. Mitral valve replacement or aortic valve replacement with additional risk factor for stroke (atrial fibrillation, previous thromboembolism, left ventricular dysfunction, hypercoagulable conditions)
8. Active cancer
9. Inheritied thrombophilia, eg: Factor V Leiden, Protein C and S deficiencies, Antithrombin deficiency, Prothrombin 20210A mutations
10. Acquired thrombophilia, eg: Lupus anticoagulant, antiphospholipid antibody syndrome
11. Patients taking clopidogrel (Plavix), ticagrelor(Brilinta), or prasugrel (Effient) or any other antiplatelet medication (except for aspirin 81 mg)
12. Patients unable to get intravenous tranexamic acid (TXA) for any reason
13. Patients requiring anticoagulant treatment prior to surgery
14. History of stroke or trans-ischemic attack
15. Serum creatinine > 2.8 mg/dl
16. History of hepatic failure
17. Any medical condition that in the opinion of the investigator would require special fluid management protocols during or after surgery
18. Allergy to TXA
19. Preoperative hemoglobin < 11
20. Preoperative platelets < 150,000
21. Blood transfusion within 1 month of surgery
22. ASA classification IV or V
23. Patients who are unwilling to undergo blood transfusion, if necessary
24. Evidence of active (systemic or local) infection at time of surgery
25. Patients who have habitual opioid use
26. Patients who have a psychiatric or mental illness which could impair the consent process or ability to complete patient-reported questionnaires
27. Fixed motor deficit affecting functional assessment of the knee
28. Patients unable to have spinal anesthesia
29. Patients receiving erythropoietin therapy for anemia
30. Patients who are unable to stop their daily aspirin, aspirin-like products, and/or non-steroidal anti-inflammatory agents 7 days prior to surgery for any reason
31. Patients with a contraindication for the pneumatic tourniquet applied in the operating room

90 days

This clinical trial is designed to compare two commercially available medical devices commonly used in surgical procedures. The devices were used according to the manufacture's guidelines. The clinical trial assessed patients for any return to OR due to bleeding or a hematoma, delayed wound healing, wound infections, any venous thromboembolism events, and skin burns.

Blinding of the principal investigator and operating staff is not possible. However, all attempts will be made to keep this information from the hospital staff caring for the patients in the postoperative period. The patient and the postoperative hospital staff will be blinded to the treatment arm. The OR staff will be trained not to discuss this information with the patient. During the transition of care from the OR to the Post Anesthetic Care Unit (PACU) the treatment arm will not be included in the verbal patient report. The lack of this information is not required to effectively manage the patient in the postoperative period and will not affect patient care. Postoperatively medical care is managed by the hospitalist, medical doctors specializing in the care of hospitalized patients.